|
May 14
|
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
|
|
May 9
|
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
|
|
Mar 27
|
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
|
|
Mar 21
|
Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges
|
|
Mar 21
|
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
|
|
Mar 13
|
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
|
|
Mar 7
|
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
|
|
Mar 5
|
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
|
|
Nov 28
|
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
|
|
Aug 23
|
Pyxis Oncology Successfully Completes Acquisition of Apexigen
|
|
May 30
|
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
|
|
May 24
|
Pyxis Oncology to Acquire Apexigen
|
|
Mar 31
|
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 30
|
Pyxis Stock Is Up 170% This Week. How Much Higher Can It Go?
|
|
Mar 22
|
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
|